ArticleChemical science2022
Peptide epitope-imprinted polymer microarrays for selective protein recognition. Application for SARS-CoV-2 RBD protein.
Article in Chemical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 54 citations in OpenAlex.
- Analytical applications of molecularly imprinted polymers: a personal view.Analytical and bioanalytical chemistry · 2026Review
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- Progress and Perspectives of Molecular Imprinting Methods in the Development of Electrochemical Protein Biosensors.Biosensors · 2026Review
- Nano-engineered biomimetic materials: toward point-of-care diagnosis of infectious diseases.Mikrochimica acta · 2025Review
- Molecularly imprinted nanogels as synthetic recognition materials for the ultrasensitive detection of periodontal disease biomarkers.Analytical and bioanalytical chemistry · 2024Article
- Article
- Specific features of epitope-MIPs and whole-protein MIPs as illustrated for AFP and RBD of SARS-CoV-2.Mikrochimica acta · 2024Article
- Review
- Imprinted Polymers on the Route to Plastibodies for Biomacromolecules (MIPs), Viruses (VIPs), and Cells (CIPs).Advances in biochemical engineering/biotechnology · 2024Review
- Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants.Global challenges (Hoboken, NJ) · 2023Article
- Molecularly Imprinted Polymer-Based Sensors for SARS-CoV-2: Where Are We Now?Biomimetics (Basel, Switzerland) · 2022Review
- Biosensors for the Determination of SARS-CoV-2 Virus and Diagnosis of COVID-19 Infection.International journal of molecular sciences · 2022Review
- An insight into polyscopoletin electrosynthesis by a quality-by-design approach.Journal of materials science · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We introduce a practically generic approach for the generation of epitope-imprinted polymer-based microarrays for protein recognition on surface plasmon resonance imaging (SPRi) chips. The SPRi platform allows the subsequent rapid screening of target binding kinetics in a multiplexed and label-free manner. The versatility of such microarrays, both as synthetic and screening platform, is demonstrated through developing highly affine molecularly imprinted polymers (MIPs) for the recognition of the receptor binding domain (RBD) of SARS-CoV-2 spike protein. A characteristic nonapeptide GFNCYFPLQ from the RBD and other control peptides were microspotted onto gold SPRi chips followed by the electrosynthesis of a polyscopoletin nanofilm to generate in one step MIP arrays. A single chip screening of essential synthesis parameters, including the surface density of the template peptide and its sequence led to MIPs with dissociation constants (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.